PBDA.F

Healthcare Biotechnology

Protalix BioTherapeutics, Inc.

€2.38

+0.00 +0.00% today

Price History

Not enough data

Key Stats

Market Cap

191.36M

Avg Volume

P/E (TTM)

11.88

EPS

€0.20

52W High

€2.66

52W Low

€1.36

Div. Yield

0.0%

Valuation

Forward P/E

59.38

P/B Ratio

3.11

P/S Ratio

2.37

EV/EBITDA

6.43

EV/Revenue

1.98

Margins

Gross Margin 45.8%

Operating Margin 23.5%

Net Margin 23.5%

EBITDA Margin 30.8%

Growth & Returns

Revenue Growth (YoY)

27.1%

Earnings Growth (YoY)

2241.1%

Earnings Growth (QoQ)

2203.0%

Return on Equity

31.2%

Return on Assets

15.4%

Liquidity & Leverage

Current Ratio

2.94

Quick Ratio

1.82

Debt / Equity

0.13

Total Cash

40.66M

Total Debt

9.21M

About

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack, New Jersey.